27% profits every 20 days?
This is what Nic Chahine averages with his options buys. Not selling covered calls or spreads... BUYING options. Most traders don't even have a winning percentage of 27% buying options. He has an 83% win rate. Here's how he does it.
- The FDA informed Sarepta Therapeutics Inc (NASDAQ:SRPT) that it requires modest additional time to complete the review of its SRP-9001 (delandistrogene moxeparvovec) for Duchenne muscular, including final label negotiations and postmarketing commitment discussions.
- Last week, FDA's Cellular, Tissue and Gene Therapies Advisory Committee (CTGTAC) voted 8 to 6 in support of accelerated approval of Sarepta's SRP-9001.
- The agency has extended the review date from May 29 to June 22.
- Following discussions with FDA, the agency has indicated that subject to the completion of the BLA review, it is working toward potentially granting an accelerated approval for SRP-9001, initially for use in Duchenne patients ages 4-5 years old.
- EMBARK Phase 3 trial of SRP-9001 is the proposed confirmatory study.
- Related: Sarepta Therapeutic Shares Surge 25% Following Favorable Gene Therapy Vote; Analyst Anticipates Huge Earnings Swing In 2024.
- The agency has informed Sarepta that, in addition to confirming the results of the initial BLA approval, if the trial meets its objectives, the agency intends to entertain a non-age-restricted expansion of the SRP-9001 label based on the review of the EMBARK data.
- EMBARK is fully enrolled, with top-line results expected in the fourth quarter of 2023.
- Price Action: SRPT shares are down 9.44% at $133 on the last check Wednesday.
27% profits every 20 days?
This is what Nic Chahine averages with his options buys. Not selling covered calls or spreads... BUYING options. Most traders don't even have a winning percentage of 27% buying options. He has an 83% win rate. Here's how he does it.
ENTER TO WIN $500 IN STOCK OR CRYPTO
Enter your email and you'll also get Benzinga's ultimate morning update AND a free $30 gift card and more!